Factors affecting hepatitis C treatment The major virologic and host factors affecting sustained virologic response (SVR) include HCV RNA genotype, baseline viral load, lipid metabolism disorders, and the degree of hepatic pathologic injury. Among them, genotype is the most important predictor of treatment response; in addition, dynamic changes in HCV RNA levels at weeks 0, 4, 12, 24, and 48 during treatment are clinically valuable predictive tools, and should therefore be monitored dynamically for more rational and individualized treatment. The risk of diabetes mellitus in patients with chronic hepatitis C is significantly higher than that of the general population, and they are prone to fat metabolism disorders that induce hepatic steatosis; at the same time, the likelihood of liver fibrosis or cirrhosis is increased after hepatic steatosis, and at this time, the SVR of the patients for antiviral drug therapy is reduced. Therefore, if the patient has the above lesions, we should emphasize the controllable factors (such as hepatic steatosis and insulin resistance), and take the initiative to use pharmacological interventions in conjunction with antiviral therapy. Pursuing the optimal balance between efficacy and safety of ribavirin in hepatitis C The combination of pegylated interferon + ribavirin can achieve a relatively satisfactory SVR rate due to the ability to achieve an early virological response, to maintain HCV RNA negativity during the treatment period, and to reduce the relapse rate at the end of the course of treatment, and ribavirin is by no means dispensable in the treatment of chronic hepatitis C. Ribavirin has been shown to be an essential component of chronic hepatitis C treatment, and has played an important role. As awareness of the importance of ribavirin grows, more and more experts are pointing out that improving outcomes in patients with refractory hepatitis C requires not only an increase in the dose of pegylated interferon, but also an increase in the dose of ribavirin. Several studies have shown that throughout combination therapy for hepatitis C, the higher the starting dose of ribavirin, the higher the SVR rate in genotype 1 patients, and the higher the overall exposure dose of ribavirin in therapy, the higher the SVR rate obtained. The overall exposure dose of ribavirin affects efficacy, suggesting that when ribavirin dose reduction is necessary due to adverse events, the dose should be reduced gradually (e.g., 200 mg/d) and interruption of ribavirin therapy should be avoided. When combining Paroxetine with ribavirin for 48 weeks, a higher SVR rate was achieved at 24 weeks without ribavirin compared with discontinuation (68% versus 53%), and discontinuation also prevented breakthroughs and relapses. As a result, the three key steps to achieving success in hepatitis C treatment are: using the standard dose of ribavirin for initial treatment; maintaining the standard dose of ribavirin for as long as possible during the course of treatment; and adhering to ribavirin until the end of the course of treatment and avoiding ribavirin discontinuation. The main adverse effect of ribavirin is hemolytic anemia, so hemoglobin should be monitored frequently before, during, and after treatment. Aggressively counteracting the anemia side effects caused by ribavirin and maintaining the dosage of ribavirin may improve the efficacy of the combination regimen. The purpose of the IDEAL study was to compare the efficacy of the regimens of pegylated interferonα-2b (12KD) in combination with ribavirin and paroxetine in combination with ribavirin for the treatment of chronic hepatitis C. The study was conducted to determine the efficacy of the combination regimens. The dose adjustment of ribavirin in the pegylated interferonα-2b (12KD) group was 200 mg per dose, whereas the dose adjustment in the Pyroxene group was 600 mg per dose until discontinuation. It is clear that the trial design dosing regimen was unfavorable to Paroxetine and the results do not reflect a true Head-to-Head clinical study. Regarding the different dosing regimens in the same trial, McHutchison, one of the trial’s principal investigators, commented in an interview with Reuters on January 7, 2005: “Ribavirin is very important for viral suppression, and the design of the trial made it possible for the pegylated interferon α-2b (12KD) treatment group to receive a larger dose of ribavirin, which in turn would directly affect the trial results. , which in turn will directly affect the results of the trial, leading to a skewing of the results in favor of pegylated interferonα-2b (12KD). ”? Therefore, in order to fully utilize the important role of ribavirin in the treatment of chronic hepatitis C, it is necessary to maintain adequate levels of ribavirin medication throughout the course of treatment, as well as to closely monitor and promptly address adverse reactions in order to obtain a balance between the efficacy and safety of ribavirin. When adverse reactions occur, reduce the dose in small increments and avoid stopping the drug as much as possible.